Martin Cevallos-Cueva, MD (@MartinCevallosC) header
Martin Cevallos-Cueva, MD (@MartinCevallosC) profile picture

Researcher | Peer Reviewer | Aspiring Dermatologist

Quito, Ecuador
Joined April 2022
Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)Photo by Martin Cevallos-Cueva, MD (@MartinCevallosC)
Martin Cevallos-Cueva, MD retweeted
What makes a meta-analysis believable? In our latest issue, a new Viewpoint outlines how to identify meta-analyses that merit clinical confidence. Explore the full issue: spkl.io/60197rxth
7
166
5
411
39,659
Martin Cevallos-Cueva, MD retweeted
The 2026 #Dyslipidemia guideline expands primary prevention #statin eligibility in the US to include more than half of adults aged 30-79 years, including patients with #chronic #kidney #disease and elevated lifetime #ASCVD risk. ja.ma/3T6RJyE
4
115
4
345
21,161
Can patients with moderate-to-severe #plaquepsoriasis safely switch from #ustekinumab (UST) to its #biosimilars? Our study in #jeadv found comparable PASI 75/90/100 and PGA 0/1 response rates, safety profiles and immunogenicity across UST biosimilars doi.org/10.1111/jdv.70616 – at Rumiñahui, Ecuador
1
107
Grateful to have reached 100 citations. A small but meaningful milestone in my academic journey, and a reminder of how much I still have to learn and contribute. Thank you to my mentors and peers who have supported me along the way. #DermatologyResearch scholar.google.com/citations… – at Pichincha, Ecuador
1
85
#Icotrokinra, a first-in-class oral IL-23 antagonist, showed strong efficacy in patients with moderate-to-severe plaque #psoriasis across 5 #RCTs (n=2,755). It significantly improved IGA 0/1 and PASI 75/90/100 responses with an acceptable safety profile. doi.org/10.1007/s10787-026-0… – at Quito, Ecuador
1
132
Grateful for the opportunity to present our research at the @SocInvestDerm Annual Meeting 2026. Every abstract, every presentation and every manuscript brings me one step closer to my dream becoming a dermatologist. #dermatology #researchlife #imgjourney – at Chicago, IL
1
92
📣 BTK inhibitors, including #remibrutinib, #fenebrutinib, and #rilzabrutinib, showed promising efficacy in #chronicspontaneousurticaria, with consistent improvements in complete response and well-controlled disease across weeks 4, 8, and 12. #dermatology journals.sagepub.com/doi/10.… – at Quito, Ecuador
1
94
Advancing #science extends beyond publishing manuscripts; it also involves active participation in the #peerreview process. I am grateful for every opportunity to learn and give back to the #scientific community #skin #dermatology #research #academic #metaanalysis @JAMADerm
1
3
755
Martin Cevallos-Cueva, MD retweeted
Ruxolitinib Cream Shows Strong Benefits in Atopic Dermatitis A new updated #metaanalysis of five #randomizedtrials (n=1912) confirms that #ruxolitinib cream significantly improves #atopicdermatitis outcomes compared with vehicle. ✨ Key findings: • Higher rates of #IGA treatment success at 4 and 8 weeks • Significant improvement in #EASI75 and #itch reduction • Consistent benefits across ages and doses • Safety profile comparable to vehicle, with no increased risk of #adverseevents 📌 Takeaway: Ruxolitinib cream is an effective and well‑tolerated #topical option for managing atopic dermatitis. 🔗 doi.org/10.1111/pai.70281 #pai_journal #systematicreview #ruxolitinibcream #AD @MartinCevallosC
2
7
330
Our study shows that in patients with #AndrogenicAlopecia, single-spin #PRP #centrifugation method achieves better outcomes than double-spin PRP, increasing #hair density, terminal hair, and platelet count, while reducing vellus hair. doi.org/10.3389/fmed.2025.16…
1
175
Understanding how the tumor-intrinsic and microenvironmental factors drive cancer resistance is key to developing novel combinations and immunomodulatory strategies to overcome it. #SkinCancer #Melanoma #Immunotherapy #CheckpointInhibitors doi.org/10.1002/aac2.70000 – at Quito, Ecuador
1
187
Both #PulsedFieldAblation and vHPSD #RadiofrequencyAblation are effective and safe options for treating #AtrialFibrillation. PFA is associated with shorter procedure times but required longer fluoroscopy times. doi.org/10.36660/abc.2024084… – at Quito, Ecuador
1
151
Honored to present at #EADV congress. #BTKinhibitors show promising results for patients with #CSU inadequately controlled with antihistamines, consistently outperforming placebo at weeks 4 and 12 in UAS7=0. @eadv #chronicspontaneousurticaria #allergy #dermatology #remibrutinib – at Paris, France
2
599